Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney disease
Biotech
Biogen returns to its roots with a West Coast immunology outpost
Biogen used last year's HI-Bio buy as a chance to reestablish itself on the West Coast and return to the science that sparked its founding.
Darren Incorvaia
Nov 18, 2025 12:25pm
AbbVie to end Calico collab, lay off scientists: Stat
Nov 13, 2025 3:59pm
Otsuka's kidney disease drug halves UPCR levels in ph. 3 study
Jun 6, 2025 6:26am
Amicus pays Dimerix $30M for late-phase rare kidney disease drug
May 1, 2025 10:59am
Novartis pays $800M to buy Regulus for phase 3-ready kidney drug
Apr 30, 2025 9:30am
Arbor sails into rocky gene editing waters with $74M
Mar 18, 2025 6:30am
